PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12840708

Once-daily therapies.

Dianne Carey
View original source ↗Export metadata ↓

Abstract

Combination antiretroviral therapy is now standard treatment for HIV infection. However, adherence to these treatment regimens remains a formidable barrier, owing to their complex and demanding nature and the severity of the associated toxicities. As suboptimal adherence increases the risk of treatment failure, the need for simpler and safer regimens is imperative. A number of strategies have been used to simplify dosing regimens and reduce pill burdens. At present, several antiretroviral drugs can be used once daily, while others have demonstrated pharmacokinetic potential for once-daily dosing and a number of compounds are in clinical development. It is possible that in the future, once-daily dosing will become the standard.

Explore related subjects

Anti-Retroviral AgentsClinical Trials as TopicDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationHIV InfectionsHIV Protease InhibitorsHumansPatient ComplianceReverse Transcriptase InhibitorsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dianne Carey. 2003. Once-daily therapies.. https://pubmed.ncbi.nlm.nih.gov/12840708/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Semi-parametric accelerated failure time regression analysis with application to interval-censored HIV/AIDS data.

This paper demonstrates a way to investigate a potentially non-linear relationship between an interval-censored response variable and a continuously distributed explanatory variable. A potentially non-linear effect of a continuous explanatory variable on the response is incorporated into an accelerated failure time model, forming a partial linear model. A sieve maximum likelihood estimator (MLE) is suggested to simultaneously estimate all the parameters. The sieve MLE is shown to be asymptotically efficient and normally distributed. Simulation studies show that the proposed estimators for the scale and regression parameters are robust and efficient, and the estimator for the non-linear function is able to capture the shape of a variety of smooth non-linear functions. The model is applied to observational HIV data, where the response variable is the time to suppression of HIV viral load after initiation of antiretroviral therapy, and baseline viral load is investigated as a potentially non-linear effect.

Anti-Retroviral Agents↗